Comment on “Clinical Outcomes of Implantable Collamer Lenses for the Treatment of Myopia in Eyes with Anterior Chamber Depth (
We appreciate the authors' recognition of our effort to explore the safety and efficacy of ICL implantation in eyes with anterior chamber depths (ACD) below the conventional 3.0 mm threshold and welcome the opportunity to address their concerns. Selection Bias and Case StratificationWe acknowledge that our study was retrospective in nature and that case selection was influenced by clinical discretion.However, the use of strict preoperative screening protocols including angle assessments, endothelial cell counts when we felt warranted, and sulcus-to-sulcus measurements ensured we avoided high-risk anatomical configurations through surgeon judgement.While stratification by narrower ACD subgroups (eg, 2.5-2.7 mm) would be of interest, the limited sample size in this initial dataset precluded meaningful subgroup analysis.This is a valuable direction for future investigation. Long-Term Follow-up and Safety MonitoringThe authors correctly note that long-term surveillance is essential in evaluating delayed complications.While our followup period captured short-term outcomes, patients continue to be monitored postoperatively by referring providers at a minimum basis of annual eye exams.We agree that future studies should include prospective, longitudinal designs with standardized evaluations of vault, endothelial health, and angle dynamics using modalities such as gonioscopy and UBM/ VHF ultrasound.We maintain excellent communications with these referring providers and the patients themselves so even to date, there have been no changes to the longer term data from referring providers or new problems arising in any patients from the study. Device and Measurement ConsiderationsWe appreciate the suggestion to incorporate multi-modal imaging for confirming ACD measurements near the threshold.While the Pentacam AXL was chosen for its reproducibility and integration with our existing workflow, we agree that future protocols could benefit from supplemental imaging for borderline cases.
Authors
- Matthew Hirabayashi (ORCID: https://orcid.org/0000-0002-0925-5494)
- Taj Nasser (ORCID: https://orcid.org/0009-0000-9869-1791)
- Gurpal Virdi (ORCID: https://orcid.org/0000-0003-0123-2658)
- Gregory Parkhurst (ORCID: https://orcid.org/0000-0002-9946-8724)
- Andrew Abramson
- Anthony Vanrachack
Institutions
- Texas State University (US)
- Medical Center Ophthalmology Associates (US)
- Cincinnati Eye Institute (US)
- Beckman Laser Institute and Medical Clinic (US)
- University of Missouri (US)
Publication Details
- Journal
- Clinical ophthalmology
- Published
- 2025-08-01
- DOI
- https://doi.org/10.2147/opth.s555419
- Primary Topic
- Ophthalmology and Visual Impairment Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00